Seeking Alpha

Citigroup says to buy the dip in Bristol-Myers (BMY +1.5%). The firm believes the FDA's complete...

Citigroup says to buy the dip in Bristol-Myers (BMY +1.5%). The firm believes the FDA's complete response letter on Eliquis will be resolved quickly and should delay the U.S. launch of the drug by only by a couple of months. The delay won't significantly change its estimates, and the it maintains its a $40 price target on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|